Legato Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Legato Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,885	Closed	-$59.3K	–	769
2026 Q1	$59.3K	Sell	16,885 -1,593	-9%	-$5.09K	0.01%	709
2025 Q4	$50.4K	Buy	18,478 +1,619	+10%	+$3.75K	﹤0.01%	739
2025 Q3	$36.6K	Hold	16,859	–	–	﹤0.01%	554
2025 Q2	$29K	Sell	16,859 -221	-1%	-$550	﹤0.01%	560
2025 Q1	$56.9K	Sell	17,080 -1,138	-6%	-$5.87K	0.01%	540
2024 Q4	$135K	Hold	18,218	–	–	0.02%	530
2024 Q3	$171K	Hold	18,218	–	–	0.02%	528
2024 Q2	$146K	Buy	18,218 +131	+0.7%	+$1.4K	0.02%	528
2024 Q1	$268K	Hold	18,087	–	–	0.03%	515
2023 Q4	$147K	Buy	18,087 +642	+4%	+$3.36K	0.02%	540
2023 Q3	$79.4K	Buy	+17,445	New	+$114K	0.01%	534

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Legato Capital Management's IOVA Position: Q2 2026 in Review

Legato Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2026, closing a stake of 16,885 shares — an estimated $59.3K sold.

Legato Capital Management first reported a position in IOVA in Q3 2023 and held it in 11 quarters. The position peaked at $268K in Q1 2024. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Legato Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Legato Capital Management sold 16,885 Iovance Biotherapeutics shares in Q2 2026, an estimated $59.3K.
Legato Capital Management first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 11 quarters.
Legato Capital Management's Iovance Biotherapeutics position peaked at $268K in Q1 2024.
293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.